Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 123

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 123
---
 continue to closely monitor our funding situation and do not currently anticipate experiencing funding or liquidity shortfalls in the short term as a result of general market conditions. In addition to the ability to seek additional funding (if needed) from market and other sources, we may also manage our funding and liquidity needs by reconsidering, to the extent necessary and appropriate, our capital expenditure plans.

As of March 31, 2025, we held JPY 385.1 billion in cash and cash equivalents on hand, of which JPY 105.8 billion was cash temporarily held on behalf of third parties related to vaccine operations and a trade receivables sales program. Takeda had access to JPY 700.0 billion in an undrawn bank commitment line. In addition, we held JPY 79.3 billion of U. S. Treasury Marketable Securities (U. S. Treasuries) classified as Level 1 in the fair value hierarchy. Total liquidity available therefore was JPY 1,058.7 billion. We believe that working capital is sufficient for our current business requirements. Furthermore, we continually seek to ensure that our level of liquidity and access to capital market funding continues to be maintained to successfully support our business operations.

Table of Contents

Consolidated Cash Flows

The following table shows information about our consolidated cash flows during the fiscal years ended March 31, 2023, 2024 and 2025:

                                                                     For the fiscal year ended March 31,                                                                   
                                                                     2023                                                  2024                      2025                  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                     (billions of yen)                                                                                     
  Net cash from operating activities                                 ¥                                          977.2      ¥              716.3      ¥            1,057.2  
  Net cash used in investing activities                              (607.1)                                               (463.9)                   (367.1)               
  Net cash used in financing activities                              (709.1)                                               (354.4)                   (751.4)               
  Net decrease in cash and cash equivalents                          ¥                                        (339.1)      ¥            (101.9)      ¥             (61.3)  
  Cash and cash equivalents at the beginning of the year             849.7                                                 533.5                     457.8                 
  Effects of exchange rate changes on cash and cash equivalents      22.9                                                  26